HPV in genital cancers (at the exception of cervical cancer) and anal cancers

Presse Medicale

Volumn 43, Issue 12, 2014, Pages e423-e428

  de Sanjosé, Silvia ^a,b   Bruni, Laia ^a   Alemany, Laia ^a,b  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ANUS CANCER; ANUS CARCINOMA; ANUS DISEASE; CANCER RISK; CANCER SCREENING; CIRCUMCISION; DISEASE ASSOCIATION; GENITAL TRACT CANCER; HEAD AND NECK CANCER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; INCIDENCE; NONHUMAN; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; PENIS CANCER; PREVALENCE; PRIMARY PREVENTION; RARE DISEASE; SECONDARY PREVENTION; SHORT SURVEY; UROGENITAL TRACT INFECTION; UTERINE CERVIX CANCER; VACCINATION; VAGINA CANCER; VIRAL TROPISM; VIRUS DETECTION; VIRUS TRANSMISSION; VIRUS TYPING; VULVA CANCER; WART VIRUS; ANUS NEOPLASMS; COMPLICATION; FEMALE; GENITAL NEOPLASMS, FEMALE; GENITAL NEOPLASMS, MALE; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

ANUS NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; GENITAL NEOPLASMS, MALE; HUMANS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84923046298     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2014.10.001     Document Type: Short Survey

References (40)

1. Forman D., Bray F., Brewster D.H., et al. Cancer incidence in five continents, Vol. X (electronic version) 2014, IARC, Lyon, [Accessed 30th September 2014]. http://ci5.iarc.fr/.
2. de Martel C., Ferlay J., Franceschi S., et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012, 13:607-615.
3. Schuurman M.S., van den Einden L.C., Massuger L.F., et al. Trends in incidence and survival of Dutch women with vulvar squamous cell carcinoma. Eur J Cancer 2013, 49:3872-3880.
4. Jones R.W., Baranyai J., Stables S. Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstet Gynecol 1997, 90:448-452.
5. Kurdgelashvili G., Dores G.M., Srour S.A., et al. Incidence of potentially human papillomavirus-related neoplasms in the United States, 1978 to 2007. Cancer 2013, 119:2291-2299.
6. Somoye G.O., Mocroft A., Olaitan A. Analysis of the incidence and mortality of vulval cancer in women in South East England 1960-1999. Arch Gynecol Obstet 2009, 279:113-117.
7. Alonso I., Fusté V., delPino M., et al. Does human papillomavirus infection imply a different prognosis in vulvar squamous cell carcinoma?. Gynecol Oncol 2011, 122:509-514.
8. De Vuyst H., Clifford G.M., Nascimento M.C., et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009, 124:1626-1636.
9. Bruni L., Barrionuevo-Rosas L., Serrano B., et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in World. Summary Report 2014-08-22 2014, [Accessed 30th September 2014]. http://www.hpvcentre.net/statistics/reports/XWX.pdf.
10. de Sanjosé S., Alemany L., Ordi J., et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer 2013, 49:3450-3461.
11. World Health, Organization Tumours of the vagina. Tumours of the breast and female genital organs (IARC/WHO Classification of Tumours). International Agency for Research on Cancer 2003, 272:291-312.
12. Lilic V., Lilic G., Filipovic S., et al. Primary carcinoma of the vagina. J BUON 2010, 15:241-247.
13. Grulich A.E., van Leeuwen M.T., Falster M.O., et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007, 370:59-67.
14. Hellman K., Silfverswärd C., Nilsson B., et al. Primary carcinoma of the vagina: factors influencing the age at diagnosis. The Radium hemmet series 1956-96. Int J Gynecol Cancer 2004, 14:491-501.
15. Daling J.R., Madeleine M.M., Schwartz S.M., et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 2002, 84:263-270.
16. Herbst A.L., Ulfelder H., Poskanzer D.C. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971, 284:878-881.
17. Mittendorf R. Teratogen update: carcinogenesis and teratogenesis associated with exposure to diethylstilbestrol (DES) in utero. Teratology 1995, 51:435-445.
18. Treffers P.E., Hanselaar A.G., Helmerhorst T.J., et al. [Consequences of diethylstilbestrol during pregnancy; 50 years later still a significant problem]. Ned Tijdschr Geneeskd 2001, 145:675-680.
19. Sinno A.K., Saraiya M., Thompson T.D., et al. Human papillomavirus genotype prevalence in invasive vaginal cancer from a registry-based population. Obstet Gynecol 2014, 123:817-821.
20. Johnson L.G., Madeleine M.M., Newcomer L.M., et al. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004, 101:281-288.
21. Machalek D.A., Poynten M., Jin F., et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 2012, 13:487-500.
22. Penn I. Cancer in the immunosuppressed organ recipient. Transplant Proc 1991, 23:1771-1772.
23. Watson M., Saraiya M., Ahmed F., et al. Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods. Cancer 2008, 113:2841-2854.
24. Daling J.R., Weiss N.S., Klopfenstein L.L., et al. Correlates of homosexual behavior and the incidence of anal cancer. JAMA 1982, 247:1988-1990.
25. Frisch M., Biggar R.J., Goedert J.J. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000, 92:1500-1510.
26. Crum-Cianflone N.F., Hullsiek K.H., Marconi V.C., et al. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS 2010, 24:535-543.
27. IARC A review of human carcinogens. Part B: biological agents. IARC Working Group on the evaluation of carcinogenic risks to humans [Accessed 30th September 2014]. http://monographs.iarc.fr/ENG/Monographs/vol100B/mono100B-1.pdf.
28. Frisch M., Glimelius B., van den Brule A.J., et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med 1997, 337:1350-1358.
29. Steinau M., Unger E.R., Hernandez B.Y., et al. Human papillomavirus prevalence in invasive anal cancers in the United States before vaccine introduction. J Low Genit Tract Dis 2013, 17:397-403.
30. Bleeker M.C., Heideman D.A., Snijders P.J., et al. Penile cancer: epidemiology, pathogenesis and prevention. World J Urol 2009, 27:141-150.
31. Miralles-Guri C., Bruni L., Cubilla A.L., et al. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 2009, 62:870-878.
32. Hernandez B.Y., Goodman M.T., Unger E.R., et al. Human papillomavirus genotype prevalence in invasive penile cancers from a registry-based United States population. Front Oncol 2014, 4:9.
33. Schiller J.T., Castellsagué X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30:F123-F138.
34. Kjaer S.K., Sigurdsson K., Iversen O.E., et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009, 2:868-878.
35. Garland S., on behalf of the HPV PATRICIA Study Group Efficacy of HPV-16/18 ASO4-adjuvanted vaccine against vulvar/vaginal intraepithelial neoplasia. 27th International Papillomavirus Conference and Clinical Workshop 2011, [Accessed 30th September 2014]. http://www.hpv2011.org/pics/1/4/Abstract%20Book%204%20Late%20Sub%20WEBB%20110922.pdf.
36. Palefsky J.M., Giuliano A.R., Goldstone S., et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011, 365:1576-1585.
37. Kreimer A.R., González P., Katki H.A., et al. CVT Vaccine Group. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol 2011, 12:862-870.
38. Giuliano A.R., Palefsky J.M., Goldstone S., et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011, 364:401-411.
39. Berry J.M., Palefsky J.M., Jay N., et al. Performance characteristics of anal cytology and human papillomavirus testing in patients with high-resolution anoscopy-guided biopsy of high-grade anal intraepithelial neoplasia. Dis Colon Rectum 2009, 52:239-247.
40. Tobian A.A., Gray R.H. Male foreskin and oncogenic human papillomavirus infection in men and their female partners. Future Microbiol 2011, 6:739-745.